Renal Transplant Rejection clinical trials

Explore recruiting renal transplant rejection clinical trials.

Recruiting renal transplant rejection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Transplant Rejection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients

Belgium, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

TRANSPGx: A multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Felzartamab in late ABMR

Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study

Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients

Sweden, Spain, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Renal Transplant Rejection trials by city

Renal Transplant Rejection in Toronto Renal Transplant Rejection in Vancouver Renal Transplant Rejection in Montreal Renal Transplant Rejection in Calgary Renal Transplant Rejection in Edmonton Renal Transplant Rejection in Ottawa Renal Transplant Rejection in Winnipeg Renal Transplant Rejection in Quebec City Renal Transplant Rejection in Hamilton Renal Transplant Rejection in Kitchener Renal Transplant Rejection in London Renal Transplant Rejection in Halifax Renal Transplant Rejection in New York Renal Transplant Rejection in Los Angeles Renal Transplant Rejection in Chicago Renal Transplant Rejection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease